To further investigate the roles of CD8+ T and NK cells in TIGIT blockade combined with low-dose OX, CD8+ T cells or NK cells in tumor-bearing mice were depleted by treatment with anti-CD8β or anti-ASGM1, respectively (Figures 5A, G). This evidence concerns the gene HCRT and neoplasm.